World Investment Advisors LLC Increases Stock Position in Sanofi (NASDAQ:SNY)

World Investment Advisors LLC grew its position in Sanofi (NASDAQ:SNY - Free Report) by 1,020.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,430 shares of the company's stock after acquiring an additional 44,108 shares during the quarter. World Investment Advisors LLC's holdings in Sanofi were worth $2,791,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of SNY. Stablepoint Partners LLC raised its stake in Sanofi by 0.8% during the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company's stock valued at $1,377,000 after acquiring an additional 189 shares during the last quarter. PDS Planning Inc raised its stake in shares of Sanofi by 3.1% during the third quarter. PDS Planning Inc now owns 6,643 shares of the company's stock worth $383,000 after purchasing an additional 200 shares during the last quarter. Eagle Ridge Investment Management lifted its holdings in shares of Sanofi by 3.8% during the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company's stock worth $321,000 after purchasing an additional 203 shares during the period. Financial Advocates Investment Management grew its position in Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company's stock valued at $365,000 after buying an additional 206 shares during the last quarter. Finally, Angeles Investment Advisors LLC grew its position in Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company's stock valued at $653,000 after buying an additional 210 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on SNY shares. StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday. Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $57.50.

Sanofi Price Performance

NASDAQ:SNY traded down $0.19 during trading hours on Friday, hitting $46.80. The company's stock had a trading volume of 3,464,494 shares, compared to its average volume of 2,066,254. The company has a market capitalization of $118.77 billion, a PE ratio of 23.88, a PEG ratio of 1.24 and a beta of 0.58. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The business's 50-day moving average is $51.02 and its two-hundred day moving average is $52.04. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion during the quarter, compared to analysts' expectations of $16.59 billion. During the same quarter last year, the business earned $2.55 earnings per share. The business's revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts anticipate that Sanofi will post 4.27 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.